However, to determine associations between FANCD2 and WNT10A germline mutations and clinical manifestation, e.g., response to therapy and prognosis or tumor molecular-level alterations, there is a need for a group of patients harboring variants in the gene. The gene discussed is WNT10A; the disease is neoplasm.